Free lookups: 2/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
2 of 3 free lookups remaining Upgrade
New search Medicine profile Measles / Mumps / Rubella /Varicella Vaccine

Clinical medicine profile

Measles / Mumps / Rubella /Varicella Vaccine

Vaccine / immunological product

POM
Evidence state Source not available Reviewed 14 Aug 2026
Route
IM / SC / ORAL / ID
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
Verification required

This profile needs source confirmation

A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.

01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • Congenital or acquired immunodeficiency, pregnancy, tumors, after a high dose of systemic corticosteroids, carcinogenic or radiation therapy, active infections e.g.

Precautions

  • Suspend immunizations after infection, high dose of systemic corticosteroids, blood transfusion for at least 3 months, carcinogenic or radiation therapy.
  • Avoid I.V injection.
  • Avoid use in allergic patients, history of convulsions.
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

9 months > 12 yrs: 2 doses at an interval of at least 6 wks between doses. Alternatively, a single dose may be administered to children who have already received a single dose of MMR vaccine and/or a single dose of another varicella vaccine.

Paediatric

See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.

Renal

N/A generally.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

N/A generally.

03 Clinical use

Use, effects & interactions

Indications

  • Measles, mumps, rubella, and varicella immunization Clinical selection for Measles / Mumps / Rubella /Varicella Vaccine should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
  • Class context: Vaccine / immunological product.
  • Confirm site-specific dose, duration and monitoring before prescribing.

Adverse effects

  • [Measles] Adverse reactions vary by agent.
  • Counsel on common predictable effects and serious warning symptoms (allergy, severe rash, jaundice, unusual bleeding, severe GI symptoms, neurological changes).
  • Report suspected ADRs via national pharmacovigilance channels. [Mumps] Adverse reactions vary by agent.
  • Counsel on common predictable effects and serious warning symptoms (allergy, severe rash, jaundice, unusual bleeding, severe GI symptoms, neurological changes).
  • Report suspected ADRs via national pharmacovigilance channels.
  • Follow Kenya KEPI / MoH schedules.
  • Never freeze freeze-sensitive vaccines incorrectly.
  • Document batch and site.
  • Separate true contraindications from precautions.
04 Pharmacology

Mechanism & disposition

Vaccines present antigen to the adaptive immune system to generate protective antibodies and memory cells without causing full disease (or using attenuated/inactivated/subunit/mRNA platforms).

Vaccines present antigen to the adaptive i…Immunoglobulins provide passive temporary…
Read complete mechanism

Vaccines present antigen to the adaptive immune system to generate protective antibodies and memory cells without causing full disease (or using attenuated/inactivated/subunit/mRNA platforms). Immunoglobulins provide passive temporary immunity.

Onset

Immune response days–weeks

Duration

Months–lifelong (schedule-dependent)

Route

IM / SC / ORAL / ID

Elimination

are product-specific. Consider food effects, protein binding, hepatic CYP/UGT

Half-life

when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC. [Mumps]

05 Special populations

Pregnancy, lactation & diet

Pregnancy

[Measles] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist. [Mumps] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.

Lactation

[Measles] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data. [Mumps] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.

06 Kenya market

Brands & loaded prices

From—
Median—
Listings0
BrandManufacturerPackObserved price
No reviewed brand listings are linked yet.
07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; Professional class pharmacology (Vaccine / immunological product)
Last reviewed14 Aug 2026
EvidenceSource not available

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.